Alice Zhang

Alice Zhang founded Verge Genomics to apply network medicine and AI-driven gene expression analysis to drug discovery, developing computational approaches that identify drug targets and repurposing opportunities by analyzing disease-associated gene networks. Her platform identifies genes and pathways dysregulated in cancer through analysis of large patient transcriptomic datasets, then matches therapeutic candidates that reverse disease gene expression signatures. She has advanced AI-discovered drug candidates into clinical trials, demonstrating the clinical translatability of computationally identified therapeutic hypotheses. Her work on regulatory frameworks for AI-designed drugs has contributed to establishing standards for AI drug discovery clinical development.